share_log

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

山溪生物製藥公司宣佈在 AACR 2023 年會上接受摘要,強調 HSB-510 為實體腫瘤和白血病的新型雙功能抑制劑
Benzinga Real-time News ·  2023/02/08 07:18

An abstract highlighting the progress of the Quatramer-based dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, and navitoclax (BCL-XL/BCL-2 inhibitor) has been scheduled for presentation in a Poster Session at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida and will be published in the online Proceedings of the AACR.

已計劃在佛羅里達州奧蘭多舉行的 2023 年美國癌症研究協會(AACR)年會上的海報會議上,將在 2023 年美國癌症研究協會(AACR)年會上的海報會議上發表一個摘要,重點介紹基於 Quatramer-2 的雙靶向 PI-KΔ/HDAC6 抑製劑的進展。HSB-510

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論